Merck & Co., Inc. provided earnings guidance for full-year 2024. For the year, company expects sales to be between $63.1 billion and $64.3 billion, including a negative impact of foreign exchange of approximately 3% at mid-April 2024 exchange rates.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
127.5 USD | -0.58% | -2.80% | +16.97% |
May. 02 | Merck: encouraging results in gastric cancer | CF |
May. 01 | Merck Says Keytruda Meets Primary Endpoint in Late-Stage Gastric Cancer Trial | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+16.97% | 323B | |
+21.85% | 546B | |
-4.77% | 359B | |
+5.69% | 290B | |
+13.68% | 234B | |
+3.65% | 198B | |
-11.12% | 194B | |
+8.08% | 167B | |
-3.40% | 157B | |
+1.72% | 123B |
- Stock Market
- Equities
- MRK Stock
- News Merck & Co., Inc.
- Merck & Co., Inc. Provides Earnings Guidance for Full-Year 2024